Sales of Flebogamma® DIF to start next year:

Grifols obtains marketing licence for its Intravenous Immunoglobulin Flebogamma® DIF, in Australia

- The company is continuing with its international expansion plans by taking the first steps towards establishing itself in the plasma products market in Australia, a country with one of the highest per capita rates of intravenous immunoglobulin (IVIG) consumption in the world.

Barcelona, 14 October 2008: Grifols, the Spanish holding company which specializes in the hospital-pharmaceuticals sector and is one of the world's leading producers of plasma products, has obtained a licence to market its next-generation intravenous immunoglobulin (IVIG) Flebogamma® DIF in Australia. With this authorization from the Australian Health Authorities Grifols is continuing with its international expansion plans by taking the first steps towards establishing itself in the plasma products market in Australia, a country with one of the highest per capita rates of IVIG consumption in the world.

The company will start selling the product in Australia in 2009. Grifols already has a strong market presence in the Australian in vitro diagnostics market with its range of autoanalyzer instruments for clinical analysis in immunology and immunohematology laboratories.

About next-generation Flebogamma® DIF

Grifols started marketing its latest generation IVIG in the United States in July 2007 under the name Flebogamma® DIF, after obtaining a licence from the Food and Drug Administration. Flebogamma® DIF (Double Inactivation and Filtering) is the only polyvalent IVIG on the market whose production process includes two specific inactivation stages together with nanofiltration at 20 nanometres, significantly increasing its safety margin.

All of the output is currently manufactured at Grifols' plant in Barcelona, Spain. However, this October construction work began on a new plant for the production of Flebogamma® DIF in Los Angeles. The new factory, matching the Barcelona plant which began operating in 2007, will occupy an area of 8,800 square metres and is expected to come on stream in 2012 or 2013. The new plant, like all the engineering projects in which Grifols invests, has been designed by Grifols Engineering S.A., and this company will also be responsible for managing its construction.

The project is part of a broader investment plan worth USD 600 million, approved by the Grifols Board of Directors at the end of 2007, and is designed to ensure the future growth of the company from 2013 onwards.

Once the building licences for the Los Angeles project have been obtained, it is hoped that the new plant will start operating in 2012 or 2013, to manufacture the company's new generation IVIG, Flebogamma® DIF. This will give the company two production facilities capable of manufacturing this plasma product in order to respond to the demands of a market which has seen sustained growth in demand during the past ten years in the United States, Europe and other international markets.
About Grifols

Grifols is a holding company specialized in the pharmaceutical-hospital sector and is present in more than 90 countries. Since May 2006, it has been quoted on the Spanish Stock Market, and forms part of the Ibex-35 Spanish index of medium capitalized companies. It is the leading European company in plasma derivatives and the third largest producer in the world. In coming years, Grifols will strengthen its leading position within the industry as a vertically integrated company, thanks both to investments which have already been made and a programme of investments for the period 2008 to 2012, worth a total of 400 million euros. In terms of raw materials, Grifols can rely on the supply of plasma from 79 plasmapheresis centres in the United States, while the fractionation capacity of its manufacturing facilities in Barcelona (Spain) and Los Angeles (United States) allow it to respond to the growing demand in the market. However, the company is not resting on its laurels and has implemented an ambitious investment plan which will deliver sustained increases over the next 8 to 10 years.